Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer

被引：0

作者：

Paolo Peterlongo

Gisella Figlioli

Andrew J. Deans

Fergus J. Couch

机构：

[1] IFOM – The FIRC Institute for Molecular Oncology,Genome Diagnostics Program

[2] St Vincent’s Institute,Genome Stability Unit

[3] Fitzroy,Departments of Health Sciences Research

[4] Laboratory Medicine and Pathology,undefined

[5] and Oncology,undefined

[6] Mayo Clinic,undefined

来源：

npj Breast Cancer | / 7卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

FANCM protein truncating variants (PTVs) are emerging as risk factors for ER-negative and triple negative breast cancer. Here, we discuss evidence that greatest risk associates with PTVs, such as p.Arg658*, that extensively truncate the 2048 amino acid FANCM protein. Moreover, risks associated with other less-truncating FANCM PTVs such as p.Gln1701* and p.Gly1906Alafs12* may be amplified by additional gene variants acting as modifiers. Further studies need to be conducted taking into considerations these aspects.

引用

共 50 条

[31] Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer
Einefors, Rickard
Kogler, Ulrika
Ellberg, Carolina
Olsson, Hakan
SPRINGERPLUS, 2013, 2 : 1 - 10
[32] Significance of PELP1 in ER-Negative Breast Cancer Metastasis
Roy, Sudipa
Chakravarty, Dimple
Cortez, Valerie
De Mukhopadhyay, Keya
Bandyopadhyay, Abhik
Ahn, Jung-Mo
Raj, Ganesh V.
Tekmal, Rajeshwar R.
Sun, LuZhe
Vadlamudi, Ratna K.
MOLECULAR CANCER RESEARCH, 2012, 10 (01) : 25 - 33
[33] Oxysterol signalling is retained in ER-negative and supressed in ER-positive breast cancer
Hutchinson, Samantha
Battaglia, Sebastiano
Roberg-Larsen, Hanne
Lianto, Priscilia
Hughes, Thomas
Thorne, James
PROCEEDINGS OF THE NUTRITION SOCIETY, 2020, 79 (OCE2) : E142 - E142
[34] AgNOR analysis of ER-positive and ER-negative cells in breast cancer.
Guski, H
Winzer, KJ
Hufnagl, P
Gunther, L
EUROPEAN JOURNAL OF HISTOCHEMISTRY, 1996, 40 (04): : 341 - 341
[35] Estrogen-independent effects of ER-α36 in ER-negative breast cancer
Zhang, Jing
Li, Guangliang
Li, Zhongqi
Yu, Xiongfei
Zheng, Yi
Jin, Ketao
Wang, Haohao
Gong, Yun
Sun, Xiaoping
Teng, Xiaodong
Cao, Jiang
Teng, Lisong
STEROIDS, 2012, 77 (06) : 666 - 673
[36] Therapeutic targeting of ERβ in triple negative breast cancer
Reese, Jordan M.
Subramaniam, Malayannan
Suman, Vera J.
Wu, Xianglin
Negron, Vivian
Gingery, Anne
Pitel, Kevin S.
Shah, Sejal S.
Cunliffe, Heather E.
McCullough, Ann E.
Pockaj, Barbara A.
Spelsberg, Thomas C.
Goetz, Matthew P.
Ingle, James N.
Hawse, John R.
CANCER RESEARCH, 2015, 75
[37] AgNOR analysis of ER-positive and ER-negative tumor cells in breast cancer
Guski, E
Winzer, KJ
Hufnagl, P
Günther, L
Kaufmann, O
PROCEEDINGS OF THE GERMAN SOCIETY FOR PATHOLOGY 82ND MEETING - 1998: SOFT TISSUE TUMORS, 1998, : 470 - 470
[38] Contributions of estrogen to ER-negative breast tumor growth
Gupta, Piyush B.
Kuperwasser, Charlotte
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2006, 102 (1-5): : 71 - 78
[39] Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer
Kiiski, Johanna I.
Pelttari, Liisa M.
Khan, Sofia
Freysteinsdottir, Edda S.
Reynisdottir, Inga
Hart, Steven N.
Shimelis, Hermela
Vilske, Sara
Kallioniemi, Anne
Schleutker, Johanna
Leminen, Arto
Butzow, Ralf
Blomqvist, Carl
Barkardottir, Rosa B.
Couch, Fergus J.
Aittomaki, Kristiina
Nevanlinna, Heli
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (42) : 15172 - 15177
[40] Selective cytotoxicity of ascochlorin in ER-negative human breast cancer cell lines
Sakaguchi, K
Nakajima, H
Mizuta, N
Furukawa, C
Ozawa, S
Ando, K
Chang, YC
Yamagishi, H
Magae, J
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (01) : 46 - 50

← 1 2 3 4 5 →